Displaying drugs 15026 - 15050 of 15142 in total
R1204
R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.
Investigational
1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE
Experimental
AP5280
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
8-azaxanthine
Experimental
3,5-Diaminophthalhydrazide
Experimental
Nitrosoethane
Experimental
Napabucasin
Napabucasin has been investigated for the treatment of Colorectal Carcinoma.
Investigational
MAS825
Investigational
INS 316
INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer. It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.
Investigational
Pridopidine
Pridopidine has been used in trials studying the treatment of Huntington's Disease.
Investigational
Oxomemazine
Experimental
R-348
Investigational
Methoxyamine
Investigational
Methyl isocyanate
Methyl isocyanate has been investigated for the treatment of Nosocomial Pneumonia.
Investigational
9-Deazahypoxanthine
Experimental
Benzoctamine
Benzoctamine is a drug with two main uses. It can be used as a sedative which does not depress the respiratory system, but rather stimulates it. It can also be used as an anxiolytic with the same efficacy as chlordiazepoxide for treating anxiety neurosis.
Experimental
2-Methyl-3-(2-Aminothiazolo)Propanal
Experimental
ALKS 27
ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD). Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.
Investigational
Ezurpimtrostat
Investigational
KB002
KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
Investigational
Bioymifi
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
Displaying drugs 15026 - 15050 of 15142 in total